Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | USP5 | P45974 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | FPR2 | P25090 | 3/20 | 0.59 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219839 | 0.92 | MAPT (0.66) | MEN1KMT2AMAPTSMN1; SMN2USP5 | |
| SCHEMBL13489653 | 0.90 | SMN1; SMN2 (0.68) | MEN1KMT2AMAPTSMN1; SMN2USP5 | |
| SCHEMBL3219665 | 0.88 | MAPT (0.89) | MEN1KMT2AMAPTSMN1; SMN2FPR2 | |
| SCHEMBL12660313 | 0.85 | MEN1 (0.65) | MEN1KMT2AMAPTSMN1; SMN2USP5 | |
| SCHEMBL3219676 | 0.85 | MEN1 (0.61) | MEN1KMT2AMAPTSMN1; SMN2FPR2 | |
| SCHEMBL3210439 | 0.84 | MEN1 (0.57) | MEN1KMT2AMAPTSMN1; SMN2HTR2C | |
| SCHEMBL3222003 | 0.83 | HTR2C (0.62) | MEN1KMT2AMAPTSMN1; SMN2HTR2C | |
| SCHEMBL3213292 | 0.83 | MAPT (0.60) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL3215019 | 0.82 | MEN1 (0.61) | MEN1KMT2AMAPTSMN1; SMN2FPR2 | |
| SCHEMBL3201810 | 0.82 | HTR2C (0.63) | MEN1KMT2AMAPTSMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | MEN1 1354/4885KMT2A 1609/4885MAPT 3352/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | MEN1 1687/4885KMT2A 1591/4885MAPT 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.